185 related articles for article (PubMed ID: 30425069)
1. Timing of treatment of smoldering myeloma: delay until progression.
Kumar SK
Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
[TBL] [Abstract][Full Text] [Related]
2. Timing of treatment of smoldering myeloma: early treatment.
Mateos MV; González-Calle V
Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H
Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma.
Cespedes DA; Gallitano SM; Bhutani D
Ann Hematol; 2022 Feb; 101(2):441-442. PubMed ID: 33860355
[No Abstract] [Full Text] [Related]
6. Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen.
Solomou EE; Marnellos P; Agathokleous A; Kyriakou G; Georgiou S; Symeonidis A
Ann Hematol; 2019 Nov; 98(11):2625-2626. PubMed ID: 31650288
[No Abstract] [Full Text] [Related]
7. Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide.
Mello RB; Vale ECSD
An Bras Dermatol; 2019 Jul; 94(3):337-340. PubMed ID: 31365665
[TBL] [Abstract][Full Text] [Related]
8. Genomic patterns of progression in smoldering multiple myeloma.
Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
[TBL] [Abstract][Full Text] [Related]
9. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
10. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T; Schoebe N; Mai S
Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.
Musto P; La Rocca F
Expert Rev Hematol; 2020 May; 13(5):501-517. PubMed ID: 32290723
[No Abstract] [Full Text] [Related]
12. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
[No Abstract] [Full Text] [Related]
14. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
Fonseca R; Gonzalez-Velez M
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
[TBL] [Abstract][Full Text] [Related]
15. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
16. Timing treatment for smoldering myeloma: is earlier better?
Hernández JÁ; Martínez-López J; Lahuerta JJ
Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.
Merz M; Hielscher T; Schult D; Mai EK; Raab MS; Hillengass J; Seckinger A; Hose D; Granzow M; Jauch A; Goldschmidt H
Leukemia; 2020 Apr; 34(4):1192-1196. PubMed ID: 31712777
[No Abstract] [Full Text] [Related]
18. Smoldering Myeloma Treatment: Who, What, and When.
Mejia Saldarriaga M; Rossi A
Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
[TBL] [Abstract][Full Text] [Related]
19. Practical approach to the management of smoldering myeloma.
Joseph NS; Lonial S
Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
[TBL] [Abstract][Full Text] [Related]
20. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
